AOD-9604 + Tesamorelin: Fat Loss Without GLP-1 Side Effects (2026)

Affiliate Disclosure: PeptideOnline.co participates in affiliate programs. Some links on this page are affiliate links, meaning we may earn a commission at no extra cost to you if you make a purchase. All supplier recommendations are based on independent evaluation.

Fat Loss Without GLP-1 Side Effects

GLP-1 receptor agonists like Semaglutide and Tirzepatide dominate the weight loss conversation — and for good reason, given their clinical data. But not everyone tolerates the GI side effects (nausea, constipation, appetite suppression), and some people want to target fat metabolism specifically without broadly suppressing appetite.

AOD-9604 and Tesamorelin offer an alternative approach: targeting fat metabolism through growth hormone pathways rather than appetite suppression. Together, they address fat loss from two angles — direct lipolysis and GH-mediated metabolic optimization.

The Stack Logic: AOD-9604 stimulates fat breakdown directly (without GH side effects). Tesamorelin triggers natural GH release, which shifts body composition toward lean mass. Neither causes the severe nausea associated with GLP-1 agonists.

AOD-9604: The Fat-Specific Fragment

AOD-9604 is a modified fragment (amino acids 177-191) of human growth hormone. It retains GH's fat-metabolizing activity while lacking its growth-promoting and diabetogenic effects — meaning it stimulates fat breakdown without affecting blood glucose, insulin, or IGF-1 levels.

Mechanism: Stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat storage) through beta-3 adrenergic receptor pathways
Clinical history: Completed Phase 2b clinical trials as an anti-obesity drug. While it didn't achieve FDA approval as a standalone drug (insufficient efficacy vs placebo for the commercial bar), the safety data was strong
FDA Category: Category 1 — cleared for compounding
Typical research dose: 300-600 mcg/day subcutaneous, typically morning fasted

Tesamorelin: GH-Releasing Powerhouse

Tesamorelin is a growth hormone-releasing hormone (GHRH) analog that's actually FDA-approved — under the brand name Egrifta — for the reduction of excess abdominal fat in HIV-associated lipodystrophy. It's one of the few GH-related peptides with robust clinical trial data for body composition changes.

Mechanism: Stimulates the pituitary gland to release natural growth hormone in a pulsatile pattern, mimicking the body's own GH secretion
Clinical data: Demonstrated significant reduction in visceral adipose tissue (VAT) — the deep abdominal fat that's most metabolically dangerous
FDA status: FDA-approved (Egrifta) for lipodystrophy; available through compounding for other uses
Typical research dose: 1-2 mg/day subcutaneous

Why Stack Them Together?

Mechanism	AOD-9604	Tesamorelin	Combined Effect
Fat breakdown	Direct lipolysis via beta-3 receptors	GH-mediated fat mobilization	Dual-pathway fat breakdown
Visceral fat	General fat reduction	Specifically targets visceral fat	Enhanced deep fat reduction
Muscle preservation	Neutral (no GH effects)	GH promotes lean mass	Better body recomposition
Blood sugar	No effect on glucose	Mild — less than exogenous GH	Minimal metabolic disruption
Appetite	No suppression	No suppression	No nausea or GI side effects

Adding MOTS-C for Metabolic Optimization

For a comprehensive non-GLP-1 fat loss protocol, some researchers add MOTS-C — a mitochondrial-derived peptide that enhances cellular energy metabolism through AMPK activation. MOTS-C improves glucose utilization and has shown anti-obesity effects in animal models, addressing the metabolic efficiency component that AOD-9604 and Tesamorelin don't directly target.

Sample Protocol

Peptide	Dose	Timing	Duration
AOD-9604	300 mcg/day	Morning, fasted	8-12 weeks
Tesamorelin	1 mg/day	Evening (before bed)	8-12 weeks
MOTS-C (optional)	5 mg, 3x/week	Morning	8-12 weeks

Note: Tesamorelin is not recommended for individuals with active malignancy due to its GH-releasing effects. Dosing protocols should be managed by a qualified healthcare provider with appropriate blood work monitoring.

AOD/Tesamorelin vs GLP-1s: Which Path?

Factor	AOD-9604 + Tesamorelin	GLP-1s (Sema/Tirz)
Weight loss magnitude	Moderate (5-10%)	Aggressive (15-24%)
GI side effects	Minimal	Common (nausea, constipation)
Appetite suppression	No	Yes (primary mechanism)
Muscle preservation	Better (GH support)	Moderate risk of muscle loss
Best for	Moderate fat loss, body recomp, GLP-1 intolerant	Significant weight loss, obesity, metabolic syndrome

Where to Source

BioPure Peptides

Code: POWER

AOD-9604, Tesamorelin, MOTS-C all available.

Shop AOD-9604 → Shop Tesamorelin → Shop MOTS-C →

Midwest Peptide

Code: POWER — 10% Off

MOTS-C and SS-31 available. Tesamorelin check availability.

Shop MOTS-C → Check Tesamorelin →

Frequently Asked Questions

Does AOD-9604 actually work for weight loss?

AOD-9604 completed Phase 2b clinical trials showing lipolytic activity (fat breakdown stimulation) without affecting blood glucose or GH levels. While it didn't meet the commercial efficacy bar for standalone FDA approval, it demonstrated a favorable safety profile and measurable fat loss effects.

Is Tesamorelin FDA approved?

Yes — Tesamorelin is FDA-approved under the brand name Egrifta for reduction of excess abdominal fat in HIV-associated lipodystrophy. It's one of the few peptides with full FDA approval.

Can you use AOD-9604 and GLP-1s together?

They work through different mechanisms and are mechanistically compatible. Some clinicians combine them, though clinical data on the specific combination is limited. Medical supervision is recommended.

How much weight can you lose with AOD-9604?

AOD-9604 typically produces moderate fat loss (5-10% body weight) when combined with diet and exercise, compared to 15-24% with GLP-1 agonists. It's better suited for body recomposition than aggressive weight loss.

Not Sure Which Peptide Is Right for You?

Take our free 60-second quiz and get personalized peptide recommendations based on your goals.

Take the Quiz →